Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2007 2
2010 5
2011 3
2012 3
2013 1
2015 1
2016 3
2017 5
2019 3
2020 5
2021 4
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. Among authors: basu s. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
Glucuronidation: driving factors and their impact on glucuronide disposition.
Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, Shi J, Zhu L, Liu Z, Wang Y, Gao S, Hu M. Yang G, et al. Among authors: basu s. Drug Metab Rev. 2017 May;49(2):105-138. doi: 10.1080/03602532.2017.1293682. Epub 2017 May 22. Drug Metab Rev. 2017. PMID: 28266877 Free PMC article. Review.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. Janku F, et al. Among authors: basu s. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Clinical Trial.
Streamlining Food Effect Assessment - Are Repeated Food Effect Studies Needed? An IQ Analysis.
Kesisoglou F, Basu S, Belubbi T, Bransford P, Chung J, Dodd S, Dolton M, Heimbach T, Kulkarni P, Lin W, Moir A, Parrott N, Pepin X, Ren X, Sharma P, Stamatopoulos K, Tistaert C, Vaidhyanathan S, Wagner C, Riedmaier AE. Kesisoglou F, et al. Among authors: basu s. AAPS J. 2023 Jun 15;25(4):60. doi: 10.1208/s12248-023-00822-5. AAPS J. 2023. PMID: 37322223
Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.
Farhan N, Cristofoletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown JD, Fang LL, Lesko LJ, Schmidt S. Farhan N, et al. Among authors: basu s. CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):199-210. doi: 10.1002/psp4.12589. Epub 2021 Feb 10. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33449439 Free PMC article.
41 results